Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATOM: Meropenem vs Ceftazidime in Severe Melioidosis
NCT00579956Phase 3Unknown
- Sponsor
- University of Oxford
- Start
- Dec 2007
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of meropenem in melioidosis (2 arms), sponsored by University of Oxford. Primary endpoint: All cause mortality. Status: unknown.
02
Drugs
meropenem
03
Conditions
melioidosis
Beyond the preview
Go deeper on NCT00579956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00579956.